CN110115713A - A kind of snore stopping liquid and preparation method thereof - Google Patents
A kind of snore stopping liquid and preparation method thereof Download PDFInfo
- Publication number
- CN110115713A CN110115713A CN201910537399.XA CN201910537399A CN110115713A CN 110115713 A CN110115713 A CN 110115713A CN 201910537399 A CN201910537399 A CN 201910537399A CN 110115713 A CN110115713 A CN 110115713A
- Authority
- CN
- China
- Prior art keywords
- mass concentration
- snore stopping
- stopping liquid
- sinapine
- sodium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000007788 liquid Substances 0.000 title claims abstract description 104
- 206010041235 Snoring Diseases 0.000 title claims abstract description 103
- 238000002360 preparation method Methods 0.000 title claims abstract description 16
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims abstract description 93
- HUJXHFRXWWGYQH-UHFFFAOYSA-O sinapine Chemical compound COC1=CC(\C=C\C(=O)OCC[N+](C)(C)C)=CC(OC)=C1O HUJXHFRXWWGYQH-UHFFFAOYSA-O 0.000 claims abstract description 84
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims abstract description 56
- ZPIKVDODKLJKIN-NSHDSACASA-N Senkyunolide Chemical compound C1CC=CC2=C1[C@H](CCCC)OC2=O ZPIKVDODKLJKIN-NSHDSACASA-N 0.000 claims abstract description 54
- KSEBMYQBYZTDHS-HWKANZROSA-M (E)-Ferulic acid Natural products COC1=CC(\C=C\C([O-])=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-M 0.000 claims abstract description 32
- KSEBMYQBYZTDHS-HWKANZROSA-N ferulic acid Chemical compound COC1=CC(\C=C\C(O)=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-N 0.000 claims abstract description 32
- 235000001785 ferulic acid Nutrition 0.000 claims abstract description 32
- 229940114124 ferulic acid Drugs 0.000 claims abstract description 32
- KSEBMYQBYZTDHS-UHFFFAOYSA-N ferulic acid Natural products COC1=CC(C=CC(O)=O)=CC=C1O KSEBMYQBYZTDHS-UHFFFAOYSA-N 0.000 claims abstract description 32
- QURCVMIEKCOAJU-UHFFFAOYSA-N trans-isoferulic acid Natural products COC1=CC=C(C=CC(O)=O)C=C1O QURCVMIEKCOAJU-UHFFFAOYSA-N 0.000 claims abstract description 32
- XLSLFPQAPYONPW-WHUHBCJBSA-N (2s,3s,4s,5r,6r)-6-[(r)-cyano(phenyl)methoxy]-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound O1[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O[C@@H](C#N)C1=CC=CC=C1 XLSLFPQAPYONPW-WHUHBCJBSA-N 0.000 claims abstract description 28
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 claims abstract description 28
- UNGXBWFICNLIRX-UHFFFAOYSA-N Laetrile Natural products NCC(OC1OC(C(O)C(O)C1O)C(=O)O)c2ccccc2 UNGXBWFICNLIRX-UHFFFAOYSA-N 0.000 claims abstract description 28
- 235000010241 potassium sorbate Nutrition 0.000 claims abstract description 28
- 229940069338 potassium sorbate Drugs 0.000 claims abstract description 28
- 239000004302 potassium sorbate Substances 0.000 claims abstract description 28
- 239000011780 sodium chloride Substances 0.000 claims abstract description 28
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims abstract description 27
- 229920000053 polysorbate 80 Polymers 0.000 claims abstract description 27
- UEUXEKPTXMALOB-UHFFFAOYSA-J tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O UEUXEKPTXMALOB-UHFFFAOYSA-J 0.000 claims abstract description 25
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 22
- 229920001223 polyethylene glycol Polymers 0.000 claims abstract description 18
- 239000002202 Polyethylene glycol Substances 0.000 claims abstract description 16
- 239000000470 constituent Substances 0.000 claims abstract description 13
- 239000000463 material Substances 0.000 claims abstract description 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 48
- 229910052757 nitrogen Inorganic materials 0.000 claims description 24
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims description 22
- 235000002906 tartaric acid Nutrition 0.000 claims description 21
- 239000011975 tartaric acid Substances 0.000 claims description 21
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 claims description 20
- 239000003610 charcoal Substances 0.000 claims description 18
- 229940079827 sodium hydrogen sulfite Drugs 0.000 claims description 17
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 claims description 17
- 239000012530 fluid Substances 0.000 claims description 16
- 239000011265 semifinished product Substances 0.000 claims description 16
- 230000004888 barrier function Effects 0.000 claims description 8
- 229920006395 saturated elastomer Polymers 0.000 claims description 8
- 238000007789 sealing Methods 0.000 claims description 8
- 238000003756 stirring Methods 0.000 claims description 8
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 4
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims 1
- 229910052700 potassium Inorganic materials 0.000 claims 1
- 239000011591 potassium Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract description 9
- 239000002994 raw material Substances 0.000 abstract description 7
- 230000000694 effects Effects 0.000 abstract description 5
- 239000007924 injection Substances 0.000 abstract description 5
- 238000002347 injection Methods 0.000 abstract description 5
- 210000005036 nerve Anatomy 0.000 abstract description 4
- 241000894006 Bacteria Species 0.000 abstract description 2
- 238000005516 engineering process Methods 0.000 abstract description 2
- 229920002556 Polyethylene Glycol 300 Polymers 0.000 description 18
- 238000000034 method Methods 0.000 description 14
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 10
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 7
- 230000000052 comparative effect Effects 0.000 description 7
- 229910052708 sodium Inorganic materials 0.000 description 7
- 239000011734 sodium Substances 0.000 description 7
- 241000700159 Rattus Species 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 150000002596 lactones Chemical class 0.000 description 6
- 210000003928 nasal cavity Anatomy 0.000 description 6
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 229920002582 Polyethylene Glycol 600 Polymers 0.000 description 3
- 208000008784 apnea Diseases 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000009736 wetting Methods 0.000 description 3
- IQVQXVFMNOFTMU-UHFFFAOYSA-N 3-butylidene-4,5-dihydro-2-benzofuran-1-one Chemical compound C1CC=CC2=C1C(=CCCC)OC2=O IQVQXVFMNOFTMU-UHFFFAOYSA-N 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 241000700157 Rattus norvegicus Species 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000006196 drop Substances 0.000 description 2
- 230000000857 drug effect Effects 0.000 description 2
- 229960001484 edetic acid Drugs 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 210000003128 head Anatomy 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 210000000214 mouth Anatomy 0.000 description 2
- 210000004400 mucous membrane Anatomy 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 235000019508 mustard seed Nutrition 0.000 description 2
- 239000007923 nasal drop Substances 0.000 description 2
- 229940100662 nasal drops Drugs 0.000 description 2
- 230000000241 respiratory effect Effects 0.000 description 2
- 230000029058 respiratory gaseous exchange Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- 206010001497 Agitation Diseases 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 206010003497 Asphyxia Diseases 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 235000009852 Cucurbita pepo Nutrition 0.000 description 1
- 241000219104 Cucurbitaceae Species 0.000 description 1
- FEWJPZIEWOKRBE-XIXRPRMCSA-N Mesotartaric acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-XIXRPRMCSA-N 0.000 description 1
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 1
- 229920001030 Polyethylene Glycol 4000 Polymers 0.000 description 1
- 229920002385 Sodium hyaluronate Polymers 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical compound OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000003026 anti-oxygenic effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 238000005660 chlorination reaction Methods 0.000 description 1
- 230000001447 compensatory effect Effects 0.000 description 1
- 239000008139 complexing agent Substances 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 210000000887 face Anatomy 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 229930005346 hydroxycinnamic acid Natural products 0.000 description 1
- 235000010359 hydroxycinnamic acids Nutrition 0.000 description 1
- 230000000147 hypnotic effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 210000003254 palate Anatomy 0.000 description 1
- JLFNLZLINWHATN-UHFFFAOYSA-N pentaethylene glycol Chemical compound OCCOCCOCCOCCOCCO JLFNLZLINWHATN-UHFFFAOYSA-N 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000004202 respiratory function Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 210000005181 root of the tongue Anatomy 0.000 description 1
- 230000003860 sleep quality Effects 0.000 description 1
- 229940010747 sodium hyaluronate Drugs 0.000 description 1
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- NGSWKAQJJWESNS-ZZXKWVIFSA-N trans-4-coumaric acid Chemical compound OC(=O)\C=C\C1=CC=C(O)C=C1 NGSWKAQJJWESNS-ZZXKWVIFSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Emergency Medicine (AREA)
- Molecular Biology (AREA)
- Pulmonology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
Abstract
The present invention relates to field of medicine preparing technology, more particularly to a kind of snore stopping liquid and preparation method thereof, the snore stopping liquid, including active constituent, auxiliary material and ionized water, the active constituent includes sinapine, ferulic acid, Senkyunolide A, laetrile, Tween-80, glycerol, sodium chloride, edetate sodium, potassium sorbate and polyethylene glycol.Snore stopping liquid provided in the present invention can be improved the excitement levels of pharyngeal nerve, and patient is made also to be able to maintain airway open in sleep, avoid the occurrence of vortex vibration, to play the role of preventing snoring；And it is without any side effects, it is suitble to patient to be used for a long time, and the preparation method of snore stopping liquid provided by the invention, can sufficiently goes out except the bacterium in raw material and injection, improve the stability and storage time of snore stopping liquid.
Description
Technical field
The present invention relates to field of medicine preparing technology, and in particular to a kind of snore stopping liquid and preparation method thereof.
Background technique
Snoring also known as snores, snore disease, is a kind of generally existing sleep phenomenon.Many people think that snoring is the minister of public works in ancient china
See used and take exception to, also some people regard snoring as the performance to sleep soundly.Long-term snoring in fact is caused by internal disease,
Saw gourds not only influence the respiratory function of patient, but also the various diseases such as easily cause hypertension and cardiovascular and cerebrovascular, are health
Formidable enemy.Since the air flue of snorer is usually narrower than normal person, the contraction of bottleneck throat muscle compensatory makes air flue when daytime is awake
It keeps opening, not block.But nerve excitability declines when nighttime sleep, of flaccid muscles, and pharyngeal blocking makes epithelium healing
It collapses, when air-flow passes through narrow positions, generates and be vortexed and cause to vibrate, to the sound of snoring occur.Snoring patient has blood oxygen to contain more
Amount decline, thus be often accompanied by hypertension, arrhythmia, blood viscosity increase, heart burden is easy to cause cardiovascular and cerebrovascular disease
The generation of disease, can jeopardize the life of patient, or die suddenly toward contact when snoring serious.
Treatment snore disease can carry out treating and using Easy pillow using the method for operation, steroids western medicine at present
Head, although however operative treatment speed is fast, that there is pain is significant, bleeding is more, risk is big, it is costly, be also easy to produce operation simultaneously
Send out the defect of disease；Although steroids western medicine has certain curative effect using nervous excitation drug, takes Western medicine pair for a long time and make
With big, health is influenced, snore stopping pillow will affect the sleep quality of patient.
Summary of the invention
In view of the deficiencies of the prior art, an object of the present invention is to provide a kind of snore stopping liquid, it can be effectively reduced
Resistance of respiratory tract improves the situation that breathing is obstructed, and without any side effects.
The second object of the present invention is to provide a kind of preparation method of snore stopping liquid.
To achieve the goals above, one aspect of the present invention provides a kind of snore stopping liquid, including active constituent, auxiliary material and ion
Water, the active constituent include sinapine, ferulic acid, Senkyunolide A, Tween-80, glycerol, chlorination
Sodium, edetate sodium, potassium sorbate and polyethylene glycol；
Wherein, the mass concentration of the sinapine is 0.8 ~ 1.5wt%；The mass concentration of the ferulic acid
For 0.08 ~ 0.75wt%；The mass concentration of the Senkyunolide A is 0.04 ~ 0.3wt%；The mass concentration of the laetrile
For 0.16 ~ 0.6wt%；The mass concentration of the Tween-80 is 1 ~ 3wt%；The mass concentration of the glycerol is 5 ~ 15wt%；It is described
The mass concentration of sodium chloride is 0.8 ~ 1.5wt%；The mass concentration of the edetate sodium is 0.3 ~ 0.8wt%；The potassium sorbate
Mass concentration be 0.02 ~ 0.05wt%；The mass concentration of the polyethylene glycol is 0.5 ~ 3wt%.
Another aspect of the present invention provides the preparation method of snore stopping liquid described in one kind, comprising the following steps:
(1) by sinapine, ferulic acid, Senkyunolide A, laetrile, tartaric acid and bisulfite
Sodium is dissolved in ionized water, obtains medical fluid A；
(2) medical charcoal is added in medical fluid A and stirs 20 ~ 40min, be then filtered removing medical charcoal, be subsequently added into tween-
80, glycerol, sodium chloride, edetate sodium, potassium sorbate and polyethylene glycol, obtain medical liquid B；
(3) medical liquid B is filtered with 0.2 ~ 0.5 μm of microporous barrier, then passes to nitrogen to nitrogen and be saturated, then in nitrogen
Filling and sealing is carried out in stream, obtains snore stopping liquid semi-finished product；
(4) sterilize snore stopping liquid semi-finished product 15 ~ 30min at 110 ~ 115 DEG C.
Through the above technical solutions, the present invention has following technical effect that
(1) by the way that active constituent sinapine, ferulic acid, foreign Rhizoma Chuanxiong are added in snore stopping liquid in the present invention
Lactone A can be improved the excitement levels of pharyngeal nerve, so that patient is also able to maintain airway open in sleep, avoids the occurrence of whirlpool
Stream vibration, to play the role of preventing snoring.
(2) by the way that Tween-80, glycerol, sodium chloride, edetate sodium, potassium sorbate to be used cooperatively in the present invention, Neng Gourun
Pharyngeal mucous membrane is slided and softened, nasal cavity and throat wetting is kept, reduces respiratory resistance, avoid the occurrence of vortex and shake, thus
Play the role of preventing snoring.
(3) snore stopping liquid provided by the invention is without any side effects, and patient is suitble to be used for a long time.
(4) preparation method of snore stopping liquid provided by the invention can sufficiently go out except the bacterium in raw material and injection, improve
The stability and storage time of snore stopping liquid.
Other features and advantages of the present invention will the following detailed description will be given in the detailed implementation section.
Specific embodiment
Detailed description of the preferred embodiments below.It should be understood that described herein specific
Embodiment is merely to illustrate and explain the present invention, and is not intended to restrict the invention.
The endpoint of disclosed range and any value are not limited to the accurate range or value herein, these ranges or
Value should be understood as comprising the value close to these ranges or value.For numberical range, between the endpoint value of each range, respectively
It can be combined with each other between the endpoint value of a range and individual point value, and individually between point value and obtain one or more
New numberical range, these numberical ranges should be considered as specific open herein.
The present invention provides a kind of snore stopping liquid, including active constituent, auxiliary material and ionized water, and the active constituent includes mustard seed
Alkali, ferulic acid, Senkyunolide A, Tween-80, glycerol, sodium chloride, edetate sodium, potassium sorbate and
Polyethylene glycol；Wherein, the mass concentration of the sinapine is 0.8 ~ 1.5wt%；The matter of the ferulic acid
Amount concentration is 0.08 ~ 0.75wt%；The mass concentration of the Senkyunolide A is 0.04 ~ 0.3wt%；The matter of the laetrile
Amount concentration is 0.16 ~ 0.6wt%；The mass concentration of the Tween-80 is 1 ~ 3wt%；The mass concentration of the glycerol be 5 ~
15wt%；The mass concentration of the sodium chloride is 0.8 ~ 1.5wt%；The mass concentration of the edetate sodium is 0.3 ~ 0.8wt%；Institute
The mass concentration for stating potassium sorbate is 0.02 ~ 0.05wt%；The mass concentration of the polyethylene glycol is 0.5 ~ 3wt%.
It was found by the inventors of the present invention that being made by sinapine, ferulic acid, Senkyunolide A cooperation
With, can be improved the excitement levels of pharyngeal nerve, make patient sleep when be also able to maintain airway open, avoid the occurrence of vortex shake
It is dynamic, to play the role of preventing snoring；In addition, by the way that Tween-80, glycerol, sodium chloride, edetate sodium, potassium sorbate are pressed
It is used cooperatively according to special ratios, additionally it is possible to lubricate and soften pharyngeal mucous membrane, keep nasal cavity and throat wetting, reduce breathing
Resistance avoids the occurrence of vortex vibration, to play the role of preventing snoring.
In the present invention, the content of active constituent is an important factor for influencing snore stopping liquid drug effect, under optimum condition, the mustard seed
The mass concentration of alkali is that 0.8 ~ 1.5wt%(for example can be 0.8wt%, 1wt%, 1.2wt%, 1.3wt%, 1.5wt% or above-mentioned two
Arbitrary value between a numerical value)；The mass concentration of the ferulic acid is that 0.2 ~ 0.36wt%(for example can be with
For 0.2wt%, 0.25wt%, 0.28wt%, 0.3wt%, 0.32wt%, the arbitrary value between 0.36wt% or above-mentioned two numerical value)；
It for example can be 0.1wt%, 0.12wt%, 0.15wt% that the mass concentration of the Senkyunolide A, which is 0.1 ~ 0.18wt%(,
Arbitrary value between 0.16wt%, 0.18wt% or above-mentioned two numerical value)；The mass concentration of the laetrile be 0.3 ~
0.5wt%(for example can be 0.3wt%, 0.35wt%, 0.4wt%, appointing between 0.45wt%, 0.5wt% or above-mentioned two numerical value
Meaning value)；It for example can be 1.5wt%, 1.8wt%, 2wt%, 2.2wt% that the mass concentration of the Tween-80, which is 1.5 ~ 2.5wt%(,
Arbitrary value between 2.5wt% or above-mentioned two numerical value)；The mass concentration of the glycerol is that 6 ~ 12wt%(for example can be
Arbitrary value between 6wt%, 8wt%, 10wt%, 12wt% or above-mentioned two numerical value)；The mass concentration of the sodium chloride be 1 ~
1.2wt%(for example can be 1wt%, the arbitrary value between 1.2wt% or above-mentioned two numerical value)；The quality of the edetate sodium is dense
It for example can be 0.5wt%, 0.6wt%, 0.7wt% that degree, which is 0.5 ~ 0.8wt%(, any between 0.8wt% or above-mentioned two numerical value
Value)；It for example can be 0.02wt%, 0.03wt%, 0.04wt% that the mass concentration of the potassium sorbate, which is 0.02 ~ 0.05wt%(,
Arbitrary value between 0.05wt% or above-mentioned two numerical value)；The mass concentration for stating polyethylene glycol is that 1 ~ 2.5wt%(for example can be
Arbitrary value between 1wt%, 1.5wt%, 2wt%, 2.5wt% or above-mentioned two numerical value).
The dissociated ion in injection can be complexed as complexing agent for auxiliary material mesotartaric acid, and sodium hydrogensulfite is as antioxidant
The antioxygenic property of injection can be improved, thus extend its storage time, under optimum condition, the mass concentration of the tartaric acid
It for example can be 0.002wt%, 0.003wt%, 0.004wt% for 0.002 ~ 0.005wt%(, 0.005wt% or above-mentioned two numerical value
Between arbitrary value)；The mass concentration of the sodium hydrogensulfite is that 0.02 ~ 0.05wt%(for example can be 0.02wt%,
Arbitrary value between 0.03wt%, 0.04wt%, 0.05wt% or above-mentioned two numerical value).
Under optimum condition, the matter of the sinapine, the ferulic acid and the Senkyunolide A
Amount concentration ratio is 1:(0.1 ~ 0.5): (0.05 ~ 0.2), preferably 1:(0.2 ~ 0.3): (0.1 ~ 0.15), more preferably 1:0.25:
0.12。
Under optimum condition, the sinapine, laetrile mass concentration ratio be 1:(0.2 ~ 0.4), more preferably 1:
0.3。
Under optimum condition, the Tween-80, glycerol mass concentration ratio be 1:3 ~ 8, more preferably 1:4 ~ 6, more preferably
1:5。
In the present invention, snore stopping liquid is direct instillation nasal cavity, and the snore stopping liquid of liquid is easy to flow out from nasal cavity, causes
In nasal cavity the snore stopping liquid effective concentration of active constituent be lower, active constituent action time it is shorter, thus make the drug effect of snore stopping liquid by
To limitation.In the present invention, polyethylene glycol is added in nasal drops, reduces the mobility of snore stopping liquid, snore stopping liquid is enable to play
Long-acting；In addition, polyethylene glycol can also make active constituent slow release, can either avoid when nasal drops is initially added dropwise,
It is uncomfortable caused by diseased region drug concentration is excessively high, it can also make sustained release drug, have the function that long-acting treatment；Poly- second
Glycol can also play moisture-keeping function to site of action, further keep nasal cavity and throat wetting, reduce respiratory resistance.
Under optimum condition, the polyethylene glycol in PEg 300, PEG400, PEG600, PEG2000 and PEG4000 at least one
Kind, it is further preferred that the PEG is 1:(2 ~ 4 according to weight ratio by PEG600 and PEg 300) it forms, it is furthermore preferred that described
PEG is made of PEG600 and PEg 300 according to weight ratio for 1:3.
The present invention also provides a kind of preparation methods of snore stopping liquid, comprising the following steps:
(1) by sinapine, ferulic acid, Senkyunolide A, laetrile, tartaric acid and bisulfite
Sodium is dissolved in ionized water, obtains medical fluid A；
(2) medical charcoal is added in medical fluid A and stirs 20 ~ 40min, be then filtered removing medical charcoal, be subsequently added into tween-
80, glycerol, sodium chloride, edetate sodium, potassium sorbate and polyethylene glycol, obtain medical liquid B；
(3) medical liquid B is filtered with 0.2 ~ 0.5 μm of microporous barrier, then passes to nitrogen to nitrogen and be saturated, then in nitrogen
Filling and sealing is carried out in stream, obtains snore stopping liquid semi-finished product；
(4) sterilize snore stopping liquid semi-finished product 15 ~ 30min at 110 ~ 115 DEG C.
Under optimum condition, total dosage of the medical charcoal is 0.05 ~ 0.15wt% of the snore stopping liquid total weight.
The present invention will be described in detail by way of examples below.
Embodiment 1
A kind of snore stopping liquid, the foreign river of the ferulic acid of sinapine, 0.25wt% including 1wt%, 0.12wt%
The laetrile of rhizome of chuanxiong lactone A, 0.3wt%, the Tween-80 of 2.5wt%, the glycerol of 15wt%, the sodium chloride of 1.2wt%, 0.6wt%
Edetate sodium, the potassium sorbate of 0.03wt%, the PEg 300 of PEG600,1.5wt% of 0.5wt%, 0.003wt% tartaric acid and
The sodium hydrogensulfite of 0.03wt%, surplus and ionized water.
The snore stopping liquid the preparation method is as follows:
(1) by 1g sinapine, 0.25g ferulic acid, 0.12g Senkyunolide A, 0.3g laetrile,
0.3g tartaric acid and 0.03g sodium hydrogensulfite are dissolved in ionized water, obtain medical fluid A；
(2) 1g medical charcoal is added in medical fluid A and stirs 30min, be then filtered removing medical charcoal, be subsequently added into spitting for 2.5g
Warm -80, PEG600,1.5g of the glycerol of 15g, the sodium chloride of 1.2g, the edetate sodium of 0.6g, the potassium sorbate of 0.03g, 0.5g
PEg 300, obtain medical liquid B；
(3) medical liquid B is filtered with 0.22 μm of microporous barrier, then passes to nitrogen to nitrogen and be saturated, then in nitrogen stream
Filling and sealing is carried out, snore stopping liquid semi-finished product are obtained；
(4) snore stopping liquid semi-finished product are sterilized 20min at 112 DEG C, obtains snore stopping liquid A1.
Embodiment 2
A kind of snore stopping liquid, the ocean of the ferulic acid of sinapine, 0.36wt% including 1.2wt%, 0.18wt%
4,5-dihydro-3-butylidene-phthalide, the laetrile of 0.5wt%, the Tween-80 of 3wt%, the glycerol of 12wt%, the sodium chloride of 1wt%, 0.5wt% according to
Ground acid sodium, the potassium sorbate of 0.05wt%, the PEg 300 of PEG600,2wt% of 0.5wt%, 0.003wt% tartaric acid and
The sodium hydrogensulfite of 0.03wt%, surplus and ionized water；
The snore stopping liquid the preparation method is as follows:
(1) by 12g sinapine, 0.36g ferulic acid, 0.18g Senkyunolide A, 0.5g vitamin
B17,0.003g tartaric acid and 0.03g sodium hydrogensulfite are dissolved in ionized water, obtain medical fluid A；
(2) 1.5g medical charcoal is added in medical fluid A and stirs 25min, be then filtered removing medical charcoal, be subsequently added into spitting for 3g
Temperature -80, the glycerol of 12g, the sodium chloride of 1g, the edetate sodium of 0.5g, the potassium sorbate of 0.05g, 0.5g PEG600,2g
PEg 300, obtains medical liquid B；
(3) medical liquid B is filtered with 0.22 μm of microporous barrier, then passes to nitrogen to nitrogen and be saturated, then in nitrogen stream
Filling and sealing is carried out, snore stopping liquid semi-finished product are obtained；
(4) snore stopping liquid semi-finished product are sterilized 30min at 110 DEG C, obtains snore stopping liquid A2.
Embodiment 3
A kind of snore stopping liquid, the foreign Rhizoma Chuanxiong of the ferulic acid of sinapine, 0.2wt% including 1wt%, 0.1wt%
The laetrile of lactone A, 0.3wt%, the Tween-80 of 2wt%, the glycerol of 6wt%, the sodium chloride of 1.2wt%, 0.8wt% according to ground
Sour sodium, the potassium sorbate of 0.02wt%, the PEg 300 of PEG600,0.7wt% of 0.3wt%, 0.004wt% tartaric acid and
The sodium hydrogensulfite of 0.04wt%, surplus and ionized water.
The snore stopping liquid the preparation method is as follows:
(1) by 10g sinapine, 0.2g ferulic acid, 0.1g Senkyunolide A, 0.3g laetrile,
0.004g tartaric acid and 0.04g sodium hydrogensulfite are dissolved in ionized water, obtain medical fluid A；
(2) 0.5g medical charcoal is added in medical fluid A and stirs 35min, be then filtered removing medical charcoal, be subsequently added into spitting for 2g
Warm -80, PEG600,0.7g of the glycerol of 6g, the sodium chloride of 1.2g, the edetate sodium of 0.8g, the potassium sorbate of 0.02g, 0.3g
PEg 300, obtain medical liquid B；
(3) medical liquid B is filtered with 0.22 μm of microporous barrier, then passes to nitrogen to nitrogen and be saturated, then in nitrogen stream
Filling and sealing is carried out, snore stopping liquid semi-finished product are obtained；
(4) snore stopping liquid semi-finished product are sterilized 15min at 115 DEG C, obtains snore stopping liquid A3.
Embodiment 4
A kind of snore stopping liquid, the foreign river of the ferulic acid of sinapine, 0.75wt% including 1.5wt%, 0.3wt%
The laetrile of rhizome of chuanxiong lactone A, 0.6wt%, the Tween-80 of 1.5wt%, the glycerol of 12wt%, the sodium chloride of 1.5wt%, 0.3wt%
Edetate sodium, the potassium sorbate of 0.05wt%, the PEg 300 of 0.5wt%, the tartaric acid of 0.002wt% and the sulfurous acid of 0.02wt%
Hydrogen sodium, surplus and ionized water.
The snore stopping liquid the preparation method is as follows:
(1) by 15g sinapine, 0.75g ferulic acid, 0.3g Senkyunolide A, 0.1g laetrile,
0.002g tartaric acid and 0.02g sodium hydrogensulfite are dissolved in ionized water, obtain medical fluid A；
(2) 1g medical charcoal is added in medical fluid A and stirs 40min, be then filtered removing medical charcoal, be subsequently added into spitting for 1.5g
Warm -80, the PEg 300 of the glycerol of 1g, the sodium chloride of 1.5g, the edetate sodium of 0.3g, the potassium sorbate of 0.05wt%, 0.5g, obtains
To medical liquid B；
(3) medical liquid B is filtered with 0.22 μm of microporous barrier, then passes to nitrogen to nitrogen and be saturated, then in nitrogen stream
Filling and sealing is carried out, snore stopping liquid semi-finished product are obtained；
(4) snore stopping liquid semi-finished product are sterilized 15min at 110 DEG C, obtains snore stopping liquid A4.
Embodiment 5
A kind of snore stopping liquid, the ocean of the ferulic acid of sinapine, 0.08wt% including 0.8wt%, 0.04wt%
4,5-dihydro-3-butylidene-phthalide, the laetrile of 0.16wt%, the Tween-80 of 1wt%, the glycerol of 5wt%, the sodium chloride of 0.8wt%, 0.8wt%
Edetate sodium, the potassium sorbate of 0.02wt%, the PEg 300 of 3wt%, the tartaric acid of 0.005wt% and the bisulfite of 0.05wt%
Sodium, surplus and ionized water.
The snore stopping liquid the preparation method is as follows:
(1) by 8g sinapine, 0.08g ferulic acid, 0.04g Senkyunolide A, 0.16g vitamin
B17,0.005g tartaric acid and 0.05g sodium hydrogensulfite are dissolved in ionized water, obtain medical fluid A；
(2) 1g medical charcoal is added in medical fluid A and stirs 20min, be then filtered removing medical charcoal, be subsequently added into spitting for 1g
Warm -80, the PEg 300 of the glycerol of 5g, the sodium chloride of 0.8g, the edetate sodium of 0.8g, the potassium sorbate of 0.02g, 3g, obtains medicine
Liquid B；
(3) medical liquid B is filtered with 0.22 μm of microporous barrier, then passes to nitrogen to nitrogen and be saturated, then in nitrogen stream
Filling and sealing is carried out, snore stopping liquid semi-finished product are obtained；
(4) snore stopping liquid semi-finished product are sterilized 30min at 115 DEG C, obtains snore stopping liquid A5.
Embodiment 6
According to the method for embodiment 1, unlike, the sinapine, the ferulic acid and the foreign river
The mass concentration ratio of rhizome of chuanxiong lactone A is 1:0.5:0.2, and raw material group becomes a kind of snore stopping liquid, sinapine, 0.5wt% including 1wt%
Ferulic acid, the Senkyunolide A of 0.2wt%, the laetrile of 0.3wt%, 2.5wt% tween-
80, the glycerol of 15wt%, the sodium chloride of 1.2wt%, the edetate sodium of 0.6wt%, the potassium sorbate of 0.03wt%, 0.5wt%
PEg 300, the tartaric acid of 0.003wt% and the sodium hydrogensulfite of 0.03wt% of PEG600,1.5wt%, surplus and ionized water, obtain
To snore stopping liquid A6.
Embodiment 7
According to the method for embodiment 1, unlike, the sinapine, the ferulic acid and the foreign river
The mass concentration ratio of rhizome of chuanxiong lactone A is 1:0.1:0.05, raw material composition are as follows: the 3- methoxyl group -4- of the sinapine of 1wt%, 0.1wt%
Hydroxycinnamic acid, the Senkyunolide A of 0.05wt%, the laetrile of 0.3wt%, the Tween-80 of 2.5wt%, 15wt% it is sweet
PEG600,1.5wt% of oil, the sodium chloride of 1.2wt%, the edetate sodium of 0.6wt%, the potassium sorbate of 0.03wt%, 0.5wt%
The sodium hydrogensulfite of PEg 300, the tartaric acid of 0.003wt% and 0.03wt%, surplus and ionized water obtain snore stopping liquid A7.
Embodiment 8
According to the method for embodiment 1, unlike, the sinapine, laetrile mass concentration ratio be 1:0.2, raw material
Composition are as follows: the sinapine of 1wt%, the ferulic acid of 0.25wt%, 0.12wt% Senkyunolide A,
The laetrile of 0.2wt%, the Tween-80 of 2.5wt%, the glycerol of 15wt%, the sodium chloride of 1.2wt%, 0.6wt% edetic acid(EDTA)
Sodium, the potassium sorbate of 0.03wt%, the PEg 300 of PEG600,1.5wt% of 0.5wt%, 0.003wt% tartaric acid and 0.03wt%
Sodium hydrogensulfite, surplus and ionized water obtain snore stopping liquid A8.
Embodiment 9
According to the method for embodiment 1, unlike, the sinapine, laetrile mass concentration ratio be 1:0.4, raw material
Composition are as follows: the sinapine of 1wt%, the ferulic acid of 0.25wt%, 0.12wt% Senkyunolide A,
The laetrile of 0.4wt%, the Tween-80 of 2.5wt%, the glycerol of 15wt%, the sodium chloride of 1.2wt%, 0.6wt% edetic acid(EDTA)
Sodium, the potassium sorbate of 0.03wt%, the PEg 300 of PEG600,1.5wt% of 0.5wt%, 0.003wt% tartaric acid and 0.03wt%
Sodium hydrogensulfite, surplus and ionized water obtain snore stopping liquid A9.
Embodiment 10
According to the method for embodiment 1, unlike, Tween-80, glycerol mass concentration ratio be 1:2, raw material composition are as follows:
The sinapine of 1wt%, the ferulic acid of 0.25wt%, the Senkyunolide A of 0.12wt%, the dimension of 0.4wt% are raw
The mountain of the Tween-80 of plain B17,2.5wt%, the glycerol of 5wt%, the sodium chloride of 1.2wt%, the edetate sodium of 0.6wt%, 0.03wt%
Potassium sorbate, the PEg 300 of PEG600,1.5wt% of 0.5wt%, the tartaric acid of 0.003wt% and the sodium hydrogensulfite of 0.03wt%,
Surplus and ionized water obtain snore stopping liquid A10.
Comparative example 1
According to the method for embodiment 1, unlike, sinapine is not contained in snore stopping liquid, obtains snore stopping liquid B1.
Comparative example 2
According to the method for embodiment 1, unlike, snore stopping liquid does not contain ferulic acid, obtains snore stopping liquid
B2。
Comparative example 3
According to the method for embodiment 1, unlike, Senkyunolide A is free of in snore stopping liquid, obtains snore stopping liquid B3.
Comparative example 4
According to the method for embodiment 1, unlike, without foreign laetrile in snore stopping liquid, snore stopping liquid B4 is obtained.
Comparative example 5
According to the method for embodiment 1, unlike, polyethylene glycol is not contained in snore stopping liquid, obtains snore stopping liquid B5.
Application method: the application method for the snore stopping liquid that the embodiment of the present invention 1 ~ 10 is prepared are as follows: 10 ~ 30min before sleeping,
3 ~ 5 drop snore stopping liquid of drop faces upward head and keeps 30 ~ 60s to oral cavity.
Experimental example
1, stability test
Snore stopping liquid A1 ~ the A13 and B1 ~ B15 that embodiment 1 ~ 13 and comparative example 1 ~ 15 are obtained are respectively in 60 DEG C, Qiang Guang (4500lx)
It is lower to place 60 days, detect its character, using the content of high performance liquid chromatography detection sinapine, and calculate sinapine containing quantitative change
Change value, wherein experimental result is as shown in table 1.
In changes of contents value=sample to be tested in content/initial sample of sinapine sinapine content × 100%
Table 1
2, efficacy evaluation
Model foundation: choosing male Wistar rat 800, weight about 300g, and free diet tests preceding adaptable fed one
It week chooses 750 good rats of the state of mind and is randomly divided into 15 groups, every group 50, after rat anesthesia, in opposite side tongue palate
Sodium Hyaluronate is injected at bow, pharyngopalatine arch and the root of the tongue, until rat apnea occurs and observes exhaling for rat after injection stops
Situation is inhaled, its death by suffocation is prevented；
Sleep monitor: after model foundation four weeks, the snore relieving of embodiment 1 ~ 10 and comparative example 1 ~ 5 is added dropwise in rat oral cavity respectively
Liquid carries out 4 hours sleep monitors, and using multiple tracks hypnotic instrument, (Neurotronick company is produced, and Polysmith sleep analysis is soft
Part) monitoring rat sleep state, experimental result is as shown in table 2.
Wherein, blank group is male Wistar rat without any processing.
AI is apnea number, and Ltime is the longest apnea time.
Table 2
The preferred embodiment of the present invention has been described above in detail, still, the tool during present invention is not limited to the embodiments described above
Body details within the scope of the technical concept of the present invention can be with various simple variants of the technical solution of the present invention are made, these letters
Monotropic type all belongs to the scope of protection of the present invention.
It is further to note that specific technical features described in the above specific embodiments, in not lance
In the case where shield, can be combined in any appropriate way, in order to avoid unnecessary repetition, the present invention to it is various can
No further explanation will be given for the combination of energy.
In addition, various embodiments of the present invention can be combined randomly, as long as it is without prejudice to originally
The thought of invention, it should also be regarded as the disclosure of the present invention.
Claims (10)
1. a kind of snore stopping liquid, including active constituent, auxiliary material and ionized water, which is characterized in that the active constituent include sinapine,
Ferulic acid, Senkyunolide A, laetrile, Tween-80, glycerol, sodium chloride, edetate sodium, sorb
Sour potassium and polyethylene glycol；
Wherein, the mass concentration of the sinapine is 0.8 ~ 1.5wt%；
The mass concentration of the ferulic acid is 0.08 ~ 0.75wt%；
The mass concentration of the Senkyunolide A is 0.04 ~ 0.3wt%；
The mass concentration of the laetrile is 0.16 ~ 0.6wt%；
The mass concentration of the Tween-80 is 1 ~ 3wt%；
The mass concentration of the glycerol is 5 ~ 15wt%；
The mass concentration of the sodium chloride is 0.8 ~ 1.5wt%；
The mass concentration of the edetate sodium is 0.3 ~ 0.8wt%；
The mass concentration of the potassium sorbate is 0.02 ~ 0.05wt%；
The mass concentration of the polyethylene glycol is 0.5 ~ 3wt%.
2. snore stopping liquid according to claim 1, which is characterized in that the mass concentration of the sinapine is 0.8 ~ 1.5wt%；
And/or
The mass concentration of the ferulic acid is 0.2 ~ 0.36wt%；And/or
The mass concentration of the Senkyunolide A is 0.1 ~ 0.18wt%；And/or
The mass concentration of the laetrile is 0.3 ~ 0.5wt%；And/or
The mass concentration of the Tween-80 is 1.5 ~ 2.5wt%；And/or
The mass concentration of the glycerol is 6 ~ 12wt%；And/or
The mass concentration of the sodium chloride is 1 ~ 1.2wt%；And/or
The mass concentration of the edetate sodium is 0.5 ~ 0.8wt%；And/or
The mass concentration of the potassium sorbate is 0.02 ~ 0.05wt%；And/or
The mass concentration of the polyethylene glycol is 1 ~ 2.5wt%.
3. snore stopping liquid according to claim 1, which is characterized in that the auxiliary material includes tartaric acid and sodium hydrogensulfite；
The mass concentration of the tartaric acid is 0.002 ~ 0.005wt%, and/or
The mass concentration of the sodium hydrogensulfite is 0.02 ~ 0.05wt%.
4. snore stopping liquid described according to claim 1 ~ any one of 3, which is characterized in that the sinapine, the 3- methoxy
The mass concentration ratio of base -4- hydroxycinnamic acid and the Senkyunolide A is 1:(0.1 ~ 0.5): (0.05 ~ 0.2).
5. snore stopping liquid according to claim 4, which is characterized in that the sinapine, the 3- methoxyl group -4- hydroxy cinnamate
The mass concentration ratio of the sour and described Senkyunolide A is 1:(0.2 ~ 0.3): (0.1 ~ 0.15).
6. snore stopping liquid described according to claim 1 ~ any one of 3, which is characterized in that the sinapine, laetrile
Mass concentration ratio is 1:0.2 ~ 0.4.
7. snore stopping liquid according to claim 6, which is characterized in that the sinapine, laetrile mass concentration ratio be
1:0.3.
8. snore stopping liquid described according to claim 1 ~ any one of 3, which is characterized in that the quality of the Tween-80, glycerol
Concentration ratio is 1:3 ~ 8.
9. the preparation method of snore stopping liquid described in a kind of any one of claim 1 ~ 8, which is characterized in that including following step
It is rapid:
(1) by sinapine, ferulic acid, Senkyunolide A, laetrile, tartaric acid and bisulfite
Sodium is dissolved in ionized water, obtains medical fluid A；
(2) medical charcoal is added in medical fluid A and stirs 20 ~ 40min, be then filtered removing medical charcoal, be subsequently added into tween-
80, glycerol, sodium chloride, edetate sodium, potassium sorbate and polyethylene glycol, obtain medical liquid B；
(3) medical liquid B is filtered with 0.2 ~ 0.5 μm of microporous barrier, then passes to nitrogen to nitrogen and be saturated, then in nitrogen
Filling and sealing is carried out in stream, obtains snore stopping liquid semi-finished product；
(4) sterilize snore stopping liquid semi-finished product 15 ~ 30min at 110 ~ 115 DEG C.
10. preparation method according to claim 7, which is characterized in that total dosage of the medical charcoal is the snore stopping liquid
0.05 ~ 0.15wt% of total weight.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910537399.XA CN110115713A (en) | 2019-06-20 | 2019-06-20 | A kind of snore stopping liquid and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910537399.XA CN110115713A (en) | 2019-06-20 | 2019-06-20 | A kind of snore stopping liquid and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN110115713A true CN110115713A (en) | 2019-08-13 |
Family
ID=67524489
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910537399.XA Pending CN110115713A (en) | 2019-06-20 | 2019-06-20 | A kind of snore stopping liquid and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110115713A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112807312A (en) * | 2020-12-30 | 2021-05-18 | 茂名市人民医院 | Liquid snore relieving composition |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011070415A1 (en) * | 2009-11-23 | 2011-06-16 | Purapharm International (Hk) Limited | Novel therapeutic methods for treating inflammation and immune system disorders |
| CN102166225A (en) * | 2010-11-29 | 2011-08-31 | 吴克 | Snore stopping liquid and preparation process thereof |
| WO2011130181A1 (en) * | 2010-04-13 | 2011-10-20 | Johns Hopkins University | Methods for treatment of sleep-related breathing disorders |
| CN104706633A (en) * | 2013-12-17 | 2015-06-17 | 上海中医药大学 | Application of Levistolide A and analogs to inhibition of Syk kinase activity |
| US20170151268A1 (en) * | 2015-01-26 | 2017-06-01 | Kaleido Biosciences, Inc. | Glycan therapeutics and related methods thereof |
| CN107510713A (en) * | 2017-10-12 | 2017-12-26 | 武汉左点科技有限公司 | A kind of formula of liquid snore stopper that snoring symptom can be mitigated or eliminated and preparation method thereof |
-
2019
- 2019-06-20 CN CN201910537399.XA patent/CN110115713A/en active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011070415A1 (en) * | 2009-11-23 | 2011-06-16 | Purapharm International (Hk) Limited | Novel therapeutic methods for treating inflammation and immune system disorders |
| WO2011130181A1 (en) * | 2010-04-13 | 2011-10-20 | Johns Hopkins University | Methods for treatment of sleep-related breathing disorders |
| CN102166225A (en) * | 2010-11-29 | 2011-08-31 | 吴克 | Snore stopping liquid and preparation process thereof |
| CN104706633A (en) * | 2013-12-17 | 2015-06-17 | 上海中医药大学 | Application of Levistolide A and analogs to inhibition of Syk kinase activity |
| US20170151268A1 (en) * | 2015-01-26 | 2017-06-01 | Kaleido Biosciences, Inc. | Glycan therapeutics and related methods thereof |
| CN107510713A (en) * | 2017-10-12 | 2017-12-26 | 武汉左点科技有限公司 | A kind of formula of liquid snore stopper that snoring symptom can be mitigated or eliminated and preparation method thereof |
Non-Patent Citations (6)
| Title |
|---|
| 夏其乐等: ""苦杏仁苷的分析、提取纯化及药理作用研究进展"", 《食品科学》 * |
| 孙云等: ""阿魏酸钠拮抗豚鼠哮喘的作用及机制研究"", 《中国药理学通报》 * |
| 左爱华等: ""洋川芎内酯A和洋川芎内酯I的降解产物研究"", 《中草药》 * |
| 张跃明等: "《国家执业药师资格考试辅导用书》", 31 July 2014, 北京：世界图书出版公司北京分公司 * |
| 王辉等: ""芥子碱平喘作用及其机制研究"", 《中草药》 * |
| 贾智慧主编: "《精点医考.临床执业医师（2017版）》", 31 January 2017, 北京：中国协和医科大学出版社 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112807312A (en) * | 2020-12-30 | 2021-05-18 | 茂名市人民医院 | Liquid snore relieving composition |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR20080059208A (en) | Method and means of preventing and treating sleep disordered breathing | |
| Basch et al. | Physical and Chemical Properties of Sputum: II. Influence of Drugs, Steam, Carbon Dioxide and Oxygen | |
| Gautier et al. | Possible alterations in brain monoamine metabolism during hypoxia-induced tachypnea in cats | |
| CN110115713A (en) | A kind of snore stopping liquid and preparation method thereof | |
| Silkoff et al. | Nasal nitric oxide does not control basal nasal patency or acute congestion following allergen challenge in allergic rhinitis | |
| EP0866711B1 (en) | Montirelin for inhibiting sleep apnea | |
| Ameli et al. | Polysomnography of 31 Mustard Gas Exposed Veterans with Complaint of â Respiratory Sleep Problem in Baqiyatallah (as) Hospital | |
| CA2408633C (en) | Management of snoring by oral administration of dimethyl sulfone | |
| CN109568333A (en) | A kind of nasal drops and preparation method thereof for treating rhinitis | |
| CN110693861A (en) | Terbutaline sulfate solution preparation for aerosol inhalation and preparation method thereof | |
| Joseph et al. | Malignant hyperthermia associated with isoflurane anesthesia | |
| Fuglsang et al. | No protection by oral terbutaline against exercise-induced asthma in children: a dose-response study | |
| CN106975045A (en) | A kind of antiviral Neulized inhalation pharmaceutical solutions and preparation method thereof | |
| Jaichandran et al. | Intracuff buffered lidocaine versus saline or air–A comparative study for smooth extubation in patients with hyperactive airways undergoing eye surgery | |
| Anderson | Hemodynamic and non-bronchial effects of ipratropium bromide | |
| CN112336735A (en) | A liquid for relieving or eliminating snore symptom, and its preparation method | |
| CN107137518A (en) | A kind of 'Zhichuanling Neulized inhalation pharmaceutical solutions and preparation method thereof | |
| Ruben | Nitrous oxide analgesia for dental patients | |
| CN115737676A (en) | Snore relieving liquid containing high-concentration polysorbate and preparation method thereof | |
| Pandya et al. | Comparative study of intraocular pressure changes with laryngeal mask airway and endotracheal tube | |
| Schmidt et al. | Ergogenic effect of inhaled β2-agonists in asthmatics | |
| CN116421620A (en) | Snore relieving composition and preparation method and application thereof | |
| Mohamed et al. | POST-EXTUBATION SORE THROAT; HOW FAR NEBULIZ | |
| CN107913331A (en) | A kind of Chinese and Western medicine compound preparation for treating acute epiglottitis and preparation method | |
| CN119302915A (en) | Escitalopram oxalate oral spray and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20190813 |